May 12, 2020 / 9:57 PM / 22 days ago

BRIEF-Opiant Pharmaceuticals Posts Q1 Loss Per Share Of $0.40

May 12 (Reuters) - Opiant Pharmaceuticals Inc:

* OPIANT PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND CORPORATE UPDATE

* Q1 LOSS PER SHARE $0.40

* Q1 EARNINGS PER SHARE ESTIMATE $-0.19 — REFINITIV IBES DATA

* Q1 2020 REVENUES OF $4.3 MILLION DRIVEN BY NARCAN NASAL SPRAY ROYALTIES OF $4.2 MILLION

* PROJECTED ROYALTIES FOR FULL-YEAR 2020 OF APPROXIMATELY $26.2 MILLION

* CASH AND CASH EQUIVALENTS OF $32.2 MILLION AND NO DEBT AS OF MARCH 31, 2020

* NOW EXPECTS TO FILE AN NDA IN EARLY 2021 ON OPNT003

* OPNT003 DEVELOPMENT PROGRAM IMPACTED BY COVID-19 RELATED TRAVEL RESTRICTIONS IN EUROPE

* NO NEED TO ACCESS GOVERNMENT PROGRAMS IN U.S. OR UK FOR COVID-19-RELATED FINANCIAL ASSISTANCE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below